Navigation Links
Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
Date:3/18/2008

New Rochelle, NY, March 18, 2008Biotechnology companies are increasingly turning to developing nations as sites for clinical trials, reports Genetic Engineering and Biotechnology News (GEN). Increasing competition for clinical trial patients in the industrialized world is one of the major reasons for the offshore move, according to an article in the March 15 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2401)

A ready supply of patients and large potential markets are other key drivers for the decision to conduct clinical trials in developing countries, notes John Sterling, Editor-in-Chief of GEN.

Developing nations also offer less competition from other ongoing clinical trials and patients and investigators are often eager to participate. In addition, biotech and pharma companies usually conduct trials in cities, as opposed to rural areas, since many developing world cities have doctors, staff, and equipment similar to conditions that are found in the West.

Nevertheless, there are cultural issues that must be addressed in some developing nations. For example, companies need to ascertain that the disease to be studied in a trial is actually recognized as a local morbidity. In many countries, mental illness, insomnia, and depression are seen as character weaknesses rather than as illnesses.

In the GEN article, insights on conducting clinical trials in developing countries are provided by Peregrine Pharmaceuticals, Integrated Clinical Trials Services, PharmaNet, Advaxis, and Pharm-Olam International.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology technology :

1. Interleukin Genetics Retains Top Life Science Communications Firms
2. On the trail of rogue genetically modified pathogens
3. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
4. deCODE Genetics Announces Full-year 2007 Financial Results
5. Genetic manipulation might model cystic fibrosis
6. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
7. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. Genetic Engineering & Biotechnology News reports on advances in miRNA
10. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
11. Honey bee invaders exploit the genetic resources of their predecessors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... ROTTERDAM, Netherlands, April 24 LyondellBasell Industries today ... voluntarily added to Lyondell Chemical Company,s reorganization filing ... to protect the European holding company against claims ... LyondellBasell Industries AF S.C.A. is a holding company ...
... Maryland have published their assembly of the domestic cow ... the genetics community. The new version of the cow ... both completeness and accuracy. The article describing their research ... Genome Biology . , The research team led ...
... (Nasdaq: KERX ) today announced the appointment of ... Executive Officer, replacing Michael S. Weiss, effective immediately. Mr. ... since September 2007. Mr. Tarnok spent the majority of ... as Finance Director -- US Manufacturing. From 2000-2007, Mr. ...
Cached Biology Technology:LyondellBasell Adds Holding Company to Chapter 11 Protection 2New cow genome sequence released 2Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... N.J., Aug. 14 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... a private placement in which it received $2.8 million ... CEO, stated, "The,proceeds of this financing will help fund ... fourth quarter of this year." At the closing, ...
... Investors Convert Debentures to Equity, JERICHO, N.Y., Aug. ... developer and supplier of consumer,biometric products, today announced that ... Series B common stock warrants that such holders,must surrender ... The Company notified holders of 375,000 series B ...
... in September issue of Nature Methods Shows Application of ... Attachment ... Expression., GENEVA, Switzerland, Aug. 21 Researchers at ... identification of novel,high-performance Genetic Elements also known as matrix ...
Cached Biology News:SyntheMed Completes $2.8 Million Equity Financing 2bioMETRX, Inc. Calls Series B Warrants 2Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines 2
Macrophage-stimulating protein receptor...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Biology Products: